Renal cell carcinoma (RCC) incidence has doubled over the past few decades. However,
death rates have remained stable as the number of incidental renal mass diagnoses …

Cardiovascular disease and cancer are 2 of the leading causes of death worldwide.
Although improvements in outcomes have been noted for both disease entities, the success …

The prevailing treatment stratagem in cancer therapy still challenges the dilemma of a
probable metastatic spread following an initial diagnosis. Including an anti-metastatic agent …

Tivozanib is a triple vascular endothelial growth factor receptor inhibitor, recently approved
for the treatment of refractory advanced renal cell carcinoma. Clinical studies showed that …

Patients with type 2 diabetes (T2D) are at a higher risk of developing renal cell carcinoma
(RCC) than the general population. In vitro and in vivo investigations of the effects of sodium …

Background/Aim: Renal cell carcinoma (RCC) presents a formidable clinical challenge due
to its aggressive behavior and limited therapeutic options. Matrix metalloproteinase-8 (MMP …

Background and Objectives: Renal cell carcinomas and upper tract urothelial carcinomas
are types of malignancies that originate in the kidneys. Each of these examples shows an …

Purpose Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of
treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a …

METHODS Surgically managed cases of RCC at our center were identified using a
retrospective chart review of all nephrectomies conducted from March 1, 2018, to February …

Abstract [eng] Small renal masses (SRMs) are stage pT1a tumours< 4 cm that make up the
majority of kidney cancers. Detection of SRMs is difficult due to their small size and low …